ProShare Advisors LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.

Quarter-by-quarter ownership
ProShare Advisors LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q2 2023$205,039
-22.0%
6,043
+2.5%
0.00%0.0%
Q4 2022$262,785
-10.3%
5,896
-31.7%
0.00%0.0%
Q1 2022$293,000
-24.5%
8,628
-14.1%
0.00%0.0%
Q4 2021$388,000
+22.0%
10,041
+70.3%
0.00%0.0%
Q3 2021$318,000
-6.5%
5,895
-42.0%
0.00%0.0%
Q2 2021$340,00010,1710.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders